Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM)

Price 292.00p on 26-07-2024 at 16:30:00
Change 8.00p 2.82%
Buy 290.00p
Sell 288.00p
Buy / Sell HCM Shares
Last Trade: Buy 1.00 at 292.00p
Day's Volume: 9,826
Last Close: 292.00p
Open: 286.00p
ISIN: KYG4672N1198
Day's Range 286.00p - 292.00p
52wk Range: 190.40p - 353.00p
Market Capitalisation: £2,493m
VWAP: 286.61745p
Shares in Issue: 854m

Recent Trades History Hutchmed (HCM)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 1 292.00p Suspected BUY Trade
15:35:07 - 26-Jul-24
Buy* 74 290.00p Automatic Execution
15:29:36 - 26-Jul-24
Buy* 56 290.00p Automatic Execution
15:28:08 - 26-Jul-24
Sell* 1 287.00p Automatic Execution
15:12:49 - 26-Jul-24
Sell* 1 287.00p SI Trade
15:12:25 - 26-Jul-24
Sell* 1 287.00p Automatic Execution
15:12:25 - 26-Jul-24
Buy* 44 291.00p Automatic Execution
14:59:26 - 26-Jul-24
Buy* 27 292.00p Automatic Execution
14:58:20 - 26-Jul-24
Buy* 40 292.00p Automatic Execution
14:46:10 - 26-Jul-24
Buy* 48 292.00p Automatic Execution
14:27:19 - 26-Jul-24

Share Price History for Hutchmed

Time period:
to
Date Open High Low Close Volume

Share News for Hutchmed

UK earnings, trading statements calendar - next 7 days

24th Jul 2024 14:45

Read More

IN BRIEF: Hutchmed's tazemetostat given priority review in China

5th Jul 2024 19:08

Hutchmed (China) Ltd - Hong Kong-based pharmaceutical company - Says new drug application for tazemetostat given priority review by the China National Medical Products Administration. Tazemetostat was developed by Epizyme Inc for the treatment of adult patients with relapsed or refractory follicular lymphoma. Drug was given accelerated approval in the US for certain patients with R/R FL and certain patients with advanced epithelioid sarcoma. Also approved in Japan for certain patients with R/R FL. The decision was supported by a phase II bridging study in China, and clinical studies conducted by Epizyme outside China. Tazemetostat was approved for use in Macau in 2023 and Hong Kong in 2024. Read More

IN BRIEF: Hutchmed China notes Takeda obtains EU approval for Fruzaqla

24th Jun 2024 10:00

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Notes that Takeda Pharmaceuticals Co Ltd received a notification from the European Commission that it has approved Fruzaqla, alias fruquintinib, as a monotherapy for adults with metastatic colorectoral cancer who have been previously treated with available standard therapies. Takeda has the exclusive worldwide license to develop, commercialise and manufacture fruquintinib outside of mainland China. Read More

Hutchmed celebrates "promising" results for sovleplenib in China

17th Jun 2024 10:32

(Alliance News) - Hutchmed (China) Ltd on Monday said its phase 3 trial of sovleplenib showed "consistent benefits" in adults with autoimmune disorder primary immune thrombocytopenia or ITP. Read More

IN BRIEF: Hutchmed (China) begins trial of menin inhibitor HMPL-506

7th Jun 2024 18:13

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Says that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in China. The first patient received their first dose on May 31. "This is a Phase I, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics and efficacy of HMPL-506 in patients with hematological malignancies. The study is divided into two phases, a dose escalation phase and a dose expansion phase. The study is expected to enroll at least 60 patients," Hutchmed says. HMPL-506 is a novel, investigational, selective small molecule inhibitor for oral administration targeting the menin protein, it explains. Read More

FTSE 100 Latest
Value8,285.71
Change99.36

Login to your account

Forgot Password?

Not Registered